BioSpace News Archive

Standard BioTools Inc. announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:00 a.m. ET.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 23, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.

Modular Medical, Inc. announced that the underwriter of the Company’s previously announced public offering has exercised in full its option to purchase an additional 1,322,534 shares of its common stock and warrants to purchase 661,267 shares of its common stock.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced that it has entered into a common share purchase agreement and registration rights agreement with an institutional investor.

Alkermes plc filed its definitive proxy statement with the U.S. Securities and Exchange Commission and issued a letter to its shareholders in connection with the Company’s upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.

AN2 Therapeutics, Inc. announced that Eric Easom, Co-Founder, President and CEO, will present at the Jefferies Healthcare Conference.

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023.

Transgene and BioInvent International AB announce positive Phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors.

Philogen S.p.A. announces the publication of the latest results of Fibromun in combination with lomustine for the treatment of glioblastoma in Science Translational Medicine describing how the combination treatment cured orthotopic glioma-bearing mice and mediated durable objective responses and major tumor shrinkage in patients with recurrent glioblastoma.

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional two years.